(Q37858944)

24 August 2017

1 reference

title

Molecular subclassification of diffuse gliomas: seeing order in the chaos (English)

1 reference

24 August 2017

3

1 reference

24 August 2017

Jason T Huse

1

1 reference

24 August 2017

Heidi S Phillips

series ordinal

2

1 reference

24 August 2017

language of work or name

1 reference

28 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

59

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

1190-1199

1 reference

DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Pseudoprogression and pseudoresponse in the treatment of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

The transcriptional network for mesenchymal transformation of brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

A hierarchy of self-renewing tumor-initiating cell types in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

A multigene predictor of outcome in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Platelet-derived growth factor and its receptor expression in human oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Gene expression profiling of gliomas strongly predicts survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Malignant astrocytic glioma: genetics, biology, and paths to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Proliferation of human malignant astrocytomas is dependent on Ras activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Genetically engineered mouse models of brain cancer and the promise of preclinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Cross-species genomics matches driver mutations and cell compartments to model ependymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Different angiogenic phenotypes in primary and secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Genetic pathways to glioblastoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

A case history of glioma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Gefitinib in the treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Gene expression profiling identifies molecular subtypes of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Distinct transcription profiles of primary and secondary glioblastoma subgroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Primary glioblastomas express mesenchymal stem-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Epidermal growth factor receptor inhibitors in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Platelet-derived growth factor in human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

Silhouettes: A graphical aid to the interpretation and validation of cluster analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

The retinoblastoma gene is involved in malignant progression of astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.21165

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/GLIA.21165

1 reference

24 August 2017

1 reference